Evidence map›Paper›PMID 41188378›Full record

ArticleScientific reports2025

Identification of potential PI3Kγ inhibitors among FDA approved drugs using integrated computational and quantum chemical approaches.

Asma Nosratzehi, Fereshteh Shiri, Pouya Karimi, Shahin Ahmadi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asma NosratzehiDepartment of Chemistry, University of Zabol, Zabol, Iran.
Fereshteh ShiriDepartment of Chemistry, University of Zabol, Zabol, Iran. fereshteh.shiri@gmail.com.
Pouya KarimiDepartment of Chemistry, University of Zabol, Zabol, Iran.
Shahin AhmadiDepartment of Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoinositide 3-kinase gamma (PI3Kγ) is recognized as a promising target for inhibiting the activity of cancer cells, leading to increased efforts to develop PI3Kγ inhibitors as potential cancer therapies. In this research, Quantitative Structure-Activity Relationship (QSAR) modeling was performed using CORAL software on a dataset comprising 243 PI3Kγ inhibitor compounds. The model enabled the prediction of the endpoint (pIC

Indexed as

Antineoplastic AgentsClass Ib Phosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsDrug ApprovalHumansLigandsQuantitative Structure-Activity RelationshipUnited StatesUnited States Food and Drug AdministrationAntineoplastic AgentsClass Ib Phosphatidylinositol 3-KinaseLigandsPhosphoinositide-3 Kinase InhibitorsPIK3CG protein, humanProtein Kinase InhibitorsMolecular dynamic simulationMonte Carlo methodPhosphoinositide 3-kinase gammaQuantum chemistryVirtual screening

Identifiers

PMID41188378
PMCPMC12586517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.